MYC and neoplasm: In cancer, the loss of miR-34a expression contributes to tumor progression by allowing the upregulation of oncogenes such as Notch1 (Notch Receptor 1), c-MYC (Cellular myelocytomatosis oncogene), and BCL2 (B cell lymphoma 2), all of which promote cell survival and proliferation (Li et al., 2021).